Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer evaluates Isogenica’s technology

This article was originally published in Scrip

Executive Summary

Pfizer is assessing Isogenica's CIS display technology for its ability to generate therapeutic peptide candidates. Financial details and therapeutic areas of the evaluation agreement were not disclosed. The CIS display technology rapidly identifies peptides, polypeptides and antibodies that bind with high affinity and specificity to any molecular target, making very large gene libraries. Earlier this month, Isogenica granted Centocor Research & Development the non-exclusive right to use the CIS display technology for the discovery of certain therapeutic proteins. Isogenica will receive multi-million pound initial licence fees over the first three years of the agreement and ongoing licence maintenance fees and milestones associated with the clinical development of products discovered through the technology. Dr Kevin FitzGerald, Isogenica's CEO, said that the company normally conducted research for other companies rather than licensing out the platform.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC020293

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel